TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience.
Pitcha ChompoopongMohamed RezkIgal MirmanSarah E BeriniP James B DyckMichelle MauermannKamal ShoumanChristopher KleinJohn R MillsDivyanshu DubeyPublished in: Journal of neurology (2023)
TS-HDS IgM has limited phenotypic or disease specificity; it was found to be positive among patients with various neuropathy phenotypes as well as patients without objective evidence of neuropathy. Clinical improvement with immunotherapy, although was observed in a small proportion of TS-HDS IgM seropositive patients, was not more frequent when compared to seronegative patients with similar presentations.